Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• GLOBOCAN2020 I. Liver Fact Sheet 2020; 2020. Available from: https://gco.iarc.fr/today/home. Accessed January 30, 2024.
   Google Scholar
• Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Nahdi NA, Younossi ZM. Management of nonalcoholic fatty liver disease in the Middle East. WJG. 2020;26(25):3528–3541. doi:10.3748/wjg.v26.i25.3528
   PubMed Web of Science ®Google Scholar
• Ogunwobi OO, Harricharran T, Huaman J, et al. Mechanisms of hepatocellular carcinoma progression. WJG. 2019;25(19):2279–2293. doi:10.3748/wjg.v25.i19.2279
   PubMed Web of Science ®Google Scholar
• Albarrak J, Al-Shamsi H. Current status of management of hepatocellular carcinoma in the Gulf region: challenges and recommendations. Cancers. 2023;15(7):2001. doi:10.3390/cancers15072001
   PubMed Web of Science ®Google Scholar
• Al-Hamdan N, Ravichandran K, Al-Sayyad J, et al. Incidence of cancer in Gulf Cooperation Council countries, 1998–2001. East Mediterr Health J. 2009;15(3):600–611.
   PubMedGoogle Scholar
• Alqahtani S, Sanai F, Alolayan A, et al. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol. 2020;26(7):1. doi:10.4103/sjg.SJG_477_20
   PubMed Web of Science ®Google Scholar
• Al-Nemari A, Al-Rawaji A, Al-Zamzani A, Al-Alyani S, Al-Shhrani Z. Cancer Incidence Report In Kingdom of Saudi Arabia 2018. Saudi Health Council; 2018.
   Google Scholar
• Althubiti M, Alfayez M. Insights on hepatocellular carcinoma in Saudi Arabia. In: Carr BI, editor. Liver Cancer in the Middle East. Springer International Publishing; 2021:247–257. doi:10.1007/978-3-030-78737-0_16
   Google Scholar
• Globocan I Estimated age-standardized incidence rates (World) in 2020, liver, both sexes, all ages, Northern Africa, Central and Western Asia Hub (Izmir); 2020. Available from: https://gco.iarc.fr/today/online-analysis-map. Accessed January 30, 2024.
   Google Scholar
• Russo FP, Zanetto A, Pinto E, et al. Hepatocellular carcinoma in chronic viral hepatitis: where do we stand? IJMS. 2022;23(1):500. doi:10.3390/ijms23010500
   Google Scholar
• Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol. 2017;8(2):229–242. doi:10.21037/jgo.2017.03.14
   PubMed Web of Science ®Google Scholar
• Abdo AA, Hassanain M, AlJumah A, et al. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines: created and endorsed by the Saudi Association for the Study of Liver Diseases and Transplantation and the Saudi Oncology Society. Ann Saudi Med. 2012;32(2):174–199. doi:10.5144/0256-4947.2012.174
   PubMed Web of Science ®Google Scholar
• Aljumah A, Babatin M, Hashim A, et al. Hepatitis B care pathway in Saudi Arabia: current situation, gaps and actions. Saudi J Gastroenterol. 2019;25(2):73. doi:10.4103/sjg.SJG_421_18
   PubMed Web of Science ®Google Scholar
• Alhuraiji A, Alaraj A, Alghamdi S, Alrbiaan A, Alrajhi AA. Viral hepatitis B and C in HIV-infected patients in Saudi Arabia. Ann Saudi Med. 2014;34(3):207–210. doi:10.5144/0256-4947.2014.207
   PubMed Web of Science ®Google Scholar
• Aljumah AA, Kuriry H, AlZunaitan M, et al. Clinical presentation, risk factors, and treatment modalities of hepatocellular carcinoma: a single tertiary care center experience. Gastroenterol Res Pract. 2016;2016:1–9. doi:10.1155/2016/1989045
   Web of Science ®Google Scholar
• Muallem Y. Epidemiology of HCV in Saudi Arabia and it’s Burden on the Health Care System. Med Case Rep. 2022;8(12):257. doi:10.36648/2471-8041.8.12.257
   Google Scholar
• Alswat K, Aljumah A, Sanai F, et al. Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030. Saudi J Gastroenterol. 2018;24(4):211. doi:10.4103/sjg.SJG_122_18
   PubMed Web of Science ®Google Scholar
• Li X, Wang X, Gao P. Diabetes mellitus and risk of hepatocellular carcinoma. Biomed Res Int. 2017;2017:1–10. doi:10.1155/2017/5202684
   Web of Science ®Google Scholar
• Al-Judaibi B, Dokus MK, Al-Hamoudi W, et al. Saudi association for the study of liver diseases and transplantation position statement on the hepatology workforce in Saudi Arabia. Saudi J Gastroenterol. 2022;28(2):101–107. doi:10.4103/sjg.sjg_576_21
   PubMed Web of Science ®Google Scholar
• Shaaban A, Salamah R, Abo Elseud Y, Mohanty A, Albarrak J. Presentation and outcomes of hepatocellular carcinoma in the arabian peninsula: a review of a single institution experience in the Sorafenib Era. J Gastrointest Cancer. 2021;52(1):85–89. doi:10.1007/s12029-019-00341-7
   PubMed Web of Science ®Google Scholar
• Cancer incidence report Saudi Arabia 2014. Saudi Health Council Saudi Cancer; 2022. Available from: https://www.nhic.gov.sa/eServices/Documents/2014.pdf. Accessed January 30, 2024.
   Google Scholar
• Rasul KI, Al-Azawi SH, Chandra P, Abou-Alfa GK, Knuth A. Status of hepatocellular carcinoma in Gulf region. Chin Clin Oncol. 2013;2(4):42. doi:10.3978/j.issn.2304-3865.2013.11.02
   PubMedGoogle Scholar
• Alkhammash M, Bugis B. A comparison review of the clinical healthcare services provided to liver disease patients in the GCC. J Basic Clin Health Sci. 2021. doi:10.30621/jbachs.854253
   Web of Science ®Google Scholar
• Sanai FM, Al Khathlan A, Al Fadhli A, et al. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait. Hepatol Int. 2021;15(4):912–921. doi:10.1007/s12072-021-10182-x
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7(12):1632–1651. doi:10.4254/wjh.v7.i12.1632
   PubMed Web of Science ®Google Scholar
• Singal AG, Hoshida Y, Pinato DJ, et al. International Liver Cancer Association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology. 2021;160(7):2572–2584. doi:10.1053/j.gastro.2021.01.233
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Maida M, Genco C, et al. Natural history of untreatable hepatocellular carcinoma: a retrospective cohort study. World J Hepatol. 2012;4(9):256–261. doi:10.4254/wjh.v4.i9.256
   PubMedGoogle Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370. doi:10.1007/s12072-017-9799-9
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi:10.1016/j.jhep.2018.03.024
   PubMed Web of Science ®Google Scholar
• Mehta N, Bhangui P, Yao FY, et al. Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020;104(6):1136–1142. doi:10.1097/TP.0000000000003174
   PubMed Web of Science ®Google Scholar
• Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7(11):2587–2596. doi:10.1111/j.1600-6143.2007.01965.x
   PubMed Web of Science ®Google Scholar
• Pommergaard HC, Rostved AA, Adam R, et al. Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. HPB. 2018;20(8):768–775. doi:10.1016/j.hpb.2018.03.002
   PubMed Web of Science ®Google Scholar
• Toso C, Meeberg G, Hernandez-Alejandro R, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology. 2015;62(1):158–165. doi:10.1002/hep.27787
   PubMed Web of Science ®Google Scholar
• Wayne JD, Lauwers GY, Ikai I, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg. 2002;235(5):722–731.
   PubMed Web of Science ®Google Scholar
• Slotta JE, Kollmar O, Ellenrieder V, Ghadimi BM, Homayounfar K. Hepatocellular carcinoma: surgeon’s view on latest findings and future perspectives. World J Hepatol. 2015;7(9):1168–1183. doi:10.4254/wjh.v7.i9.1168
   PubMedGoogle Scholar
• Lau W, Ho SKW, Yu SCH, Lai ECH, Liew C, Leung TWT. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg. 2004;240(2):299–305. doi:10.1097/01.sla.0000133123.11932.19
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–1739. doi:10.1016/S0140-6736(02)08649-X
   PubMed Web of Science ®Google Scholar
• Llovet J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–442. doi:10.1053/jhep.2003.50047
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Helmi H, Alharthi F, Madkhali A, et al. Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Nat Sci Med. 2020. doi:10.4103/JNSM.JNSM_30_19
   Google Scholar
• Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current strategies to identify patients that will benefit from TACE treatment and future directions a practical step-by-step guide. J Hepatocell Carcinoma. 2021;8:403–419. doi:10.2147/JHC.S285735
   PubMed Web of Science ®Google Scholar
• Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. LIC. 2020;9(3):245–260. doi:10.1159/000507370
   Google Scholar
• Bzeizi KI, Arabi M, Jamshidi N, et al. Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancers. 2021;13(24):6172. doi:10.3390/cancers13246172
   PubMed Web of Science ®Google Scholar
• Ghanaati H, Mohammadifard M, Mohammadifard M. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma. J Family Med Prim Care. 2021;10(10):3553–3560. doi:10.4103/jfmpc.jfmpc_2347_20
   PubMedGoogle Scholar
• D’Avola D, Granito A, de la Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022;76(5):1185–1198. doi:10.1016/j.jhep.2021.11.013
   PubMed Web of Science ®Google Scholar
• Sacco R, Conte C, Tumino E, et al. Transarterial radioembolization for hepatocellular carcinoma: a review. JHC. 2016;3:25–29. doi:10.2147/JHC.S50359
   Google Scholar
• Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with Yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther. 2016;33(5):699–714. doi:10.1007/s12325-016-0324-7
   PubMed Web of Science ®Google Scholar
• She WH, Cheung TT. Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol. 2016;1:34. doi:10.21037/tgh.2016.03.04
   PubMedGoogle Scholar
• Byrne TJ, Rakela J. Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: selecting an optimal therapy. WJT. 2016;6(2):306. doi:10.5500/wjt.v6.i2.306
   Google Scholar
• Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155–1163.e2. doi:10.1053/j.gastro.2016.08.029
   PubMed Web of Science ®Google Scholar
• Dhondt E, Lambert B, Hermie L, et al. 90 Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology.2022;303(3):699–710. doi:10.1148/radiol.211806
   PubMed Web of Science ®Google Scholar
• Kalogeridi MA, Zygogianni A, Kyrgias G, et al. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. World J Hepatol. 2015;7(1):101–112. doi:10.4254/wjh.v7.i1.101
   PubMedGoogle Scholar
• Chen CP. Role of radiotherapy in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol. 2019;7(2):183–190. doi:10.14218/JCTH.2018.00060
   PubMed Web of Science ®Google Scholar
• Torimura T, Iwamoto H. Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2042–2054. doi:10.1111/liv.15130
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Niizeki T, Nagamatsu H, et al. Survival benefit of hepatic arterial infusion chemotherapy over sorafenib in the treatment of locally progressed hepatocellular carcinoma. Cancers. 2021;13(4):646. doi:10.3390/cancers13040646
   PubMed Web of Science ®Google Scholar
• Yan L, Lin J, Ke K, et al. A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma. Transl Cancer Res. 2022;11(1):99–112. doi:10.21037/tcr-21-1839
   PubMed Web of Science ®Google Scholar
• Choi JH, Chung WJ, Bae SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82(3):469–478. doi:10.1007/s00280-018-3638-0
   PubMed Web of Science ®Google Scholar
• Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38(36):4317–4345. doi:10.1200/JCO.20.02672
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991–1001. doi:10.1016/S1470-2045(21)00151-0
   PubMed Web of Science ®Google Scholar
• Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol. 2021;13:17588359211031140. doi:10.1177/17588359211031141
   Web of Science ®Google Scholar
• Kulik L, da Fonseca LG, He AR, et al. Potential impact of IMbrave150 results in the evolving treatment landscape of advanced hepatocellular carcinoma: a multidisciplinary expert opinion. J Hepatocell Carcinoma. 2020;7:423–433. doi:10.2147/JHC.S274930
   PubMed Web of Science ®Google Scholar
• Alfadda A, Sherbeeni S, Alqutub A, et al. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: evidence from the CORDIAL cohort study. Saudi J Gastroenterol. 2022;28(6):426. doi:10.4103/sjg.sjg_73_22
   PubMed Web of Science ®Google Scholar
• Alswat K, Alanazi M, Bashmail A, et al. Validation of the EVendo score for the prediction of varices in cirrhotic patients. Saudi J Gastroenterol. 2022;28(5):378. doi:10.4103/sjg.sjg_624_21
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Kim C, Yang H, Kim I, et al. Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-Cell responses in patients with hepatocellular carcinoma. JAMA Oncol. 2022;8(12):1825. doi:10.1001/jamaoncol.2022.4733
   PubMed Web of Science ®Google Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–649. doi:10.1002/bjs.1800600817
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. JCO. 2022;40(4_suppl):379. doi:10.1200/JCO.2022.40.4_suppl.379
   Web of Science ®Google Scholar
• AstraZeneca. A randomized, open-label, multi-center Phase III study of durvalumab and tremelimumab as first-line treatment in patients with advanced hepatocellular carcinoma. clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03298451. Accessed November 1, 2022.
   Google Scholar
• Kudo M. Durvalumab plus tremelimumab: a novel combination immunotherapy for unresectable hepatocellular carcinoma. Liver Cancer. 2022;11(2):87–93. doi:10.1159/000523702
   PubMed Web of Science ®Google Scholar
• Sangro B, Chan S, Kelley R. SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2023;34(S1):168. doi:10.1016/j.annonc.2023.04.487
   Google Scholar
• Siddique O, Yoo ER, Perumpail RB, et al. The importance of a multidisciplinary approach to hepatocellular carcinoma. J Multidiscip Healthc. 2017;10:95–100. doi:10.2147/JMDH.S128629
   PubMed Web of Science ®Google Scholar
• Abaalkhail FA, Al Sebayel MI, Shagrani MA, et al. Clinical practice guidelines for liver transplantation in Saudi Arabia. SMJ. 2021;42(9):927–968. doi:10.15537/smj.2021.42.9.20210126
   Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22(34):7645–7659. doi:10.3748/wjg.v22.i34.7645
   PubMed Web of Science ®Google Scholar
• Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313. doi:10.1038/s41575-020-00395-0
   PubMed Web of Science ®Google Scholar
• Gallage S, García-Beccaria M, Szydlowska M, et al. The therapeutic landscape of hepatocellular carcinoma. Medicine. 2021;2(5):505–552. doi:10.1016/j.medj.2021.03.002
   PubMedGoogle Scholar
• Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146. doi:10.1038/s41392-020-00264-x
   PubMed Web of Science ®Google Scholar
• Granito A, Forgione A, Marinelli S, et al. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol. 2021;14:175628482110169. doi:10.1177/17562848211016959
   Web of Science ®Google Scholar
• Trevisani F, Brandi G, Garuti F, et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol. 2018;144(2):403–414. doi:10.1007/s00432-017-2556-6
   PubMed Web of Science ®Google Scholar